A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease

Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs Gantenerumab (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms GRADUATE-2
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 24 Jul 2018 Planned End Date changed from 20 Jun 2023 to 2 May 2023.
    • 24 Jul 2018 Planned primary completion date changed from 1 Jul 2022 to 31 May 2022.
    • 12 Jun 2018 According to a MorphoSys media release, first patient has been enrolled in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top